<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01886287</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-17410</org_study_id>
    <secondary_id>CSMS995AUS64T</secondary_id>
    <nct_id>NCT01886287</nct_id>
  </id_info>
  <brief_title>P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome</brief_title>
  <official_title>Phase II Study of Above-Label Octreotide-LAR in Patients With Insufficiently Controlled Carcinoid Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to investigate the effects of high-dose octreotide on
      flushing, diarrhea, and quality of life in patients whose disease-related symptoms are
      inadequately controlled by the maximum approved dose of octreotide LAR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study population will consist of patients with advanced (metastatic or unresectable)
      neuroendocrine tumors with suboptimally controlled carcinoid syndrome. While the majority of
      patients will have primary tumors of the ileocecum (midgut), any serotonin-producing
      neuroendocrine tumors will be eligible (including pancreatic, lung and unknown primary).

      All patients will be followed for adverse events and serious adverse events for 28 days
      following the last dose of above-label octreotide, or until resolution or stabilization of
      the event, whichever comes first.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual
  </why_stopped>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Improved Frequency of Diarrhea</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>The frequencies of flushing, diarrhea, and carcinoid syndrome control rating (scale 1-5) will be measured and compared at week 0 and week 12 . These measurements will be compared using two-sided non-parametric paired Wilcoxon signed-rank.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Progression Free Survival (PFS) at 6 Months</measure>
    <time_frame>At 6 months</time_frame>
    <description>Progression-free survival, defined as rate of patients alive and free of progression from the date of first study treatment to the end of trial at 6 months. Progressive disease (PD): at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Neuroendocrine Carcinoma</condition>
  <arm_group>
    <arm_group_label>Octreotide Long-acting Release (LAR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide LAR</intervention_name>
    <description>Octreotide LAR as outlined in Treatment Arm.</description>
    <arm_group_label>Octreotide Long-acting Release (LAR)</arm_group_label>
    <other_name>Sandostatin LAR®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic neuroendocrine tumors that are considered well or moderately differentiated
             (or low to intermediate grade). Patients with poorly differentiated neuroendocrine
             carcinomas or small cell carcinomas are excluded from the study.

          -  Elevated urine 5-hydroxyindoleacetic acid (5-HIAA)

          -  More than 2 bowel-movements per day OR more than 4 flushing episodes per week on
             average

          -  Patient currently on octreotide LAR 30mg every 3 or 4 weeks (for at least 3 cycles
             prior to screening)

          -  Age ≥ 18 years

          -  Minimum of four weeks since any major surgery, liver-directed therapy (embolization,
             etc.) or systemic cancer treatment other than octreotide LAR

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2

          -  Life expectancy &gt; 12 weeks

          -  Reliable contraception should be maintained throughout the study and for 3 months
             after study drug discontinuation.

          -  Signed informed consent to participate in the study must be obtained from patients
             after they have been fully informed of the nature and potential risks by the
             investigator (or his/her designee) with the aid of written information.

        Exclusion Criteria:

          -  Known hypersensitivity to somatostatin analogues

          -  Patients with poorly differentiated neuroendocrine cancers

          -  Patients with liver cirrhosis

          -  Patients receiving hemodialysis or peritoneal dialysis

          -  Patients with cachexia who, in the opinion of the investigator, may have difficulty
             tolerating intramuscular injection

          -  Patients with symptomatic cholelithiasis or biliary events within past five years (who
             have not undergone cholecystectomy)

          -  Patients with recent history (within 5 years) of pancreatitis

          -  Patients with uncontrolled diabetes (HgA1c &gt;8.0 despite adequate therapy)

          -  Women of child-bearing potential, UNLESS they are using two birth control methods

          -  Women who are pregnant or lactating

          -  HIV positive patients

          -  History of sustained ventricular tachycardia, ventricular fibrillation, advanced heart
             block, idiopathic syncope thought to be related to ventricular arrhythmia, or
             congenital long QT syndrome

          -  Risk factors for Torsades de Pointes such as cardiac failure, clinically
             significant/symptomatic bradycardia

          -  Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study

          -  History of noncompliance to medical regimens or unwillingness to comply with the
             protocol

          -  Patients who were unable to tolerate or did not benefit from above-label dose
             octreotide (&gt;30mg) in the past

          -  Concomitant use of other cancer treatments or carcinoid syndrome treatments (whether
             standard or experimental). Patients should discontinue any concomitant cancer
             medications more than two weeks prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Strosberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2013</study_first_submitted>
  <study_first_submitted_qc>June 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2013</study_first_posted>
  <results_first_submitted>January 6, 2015</results_first_submitted>
  <results_first_submitted_qc>January 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 12, 2015</results_first_posted>
  <last_update_submitted>January 6, 2015</last_update_submitted>
  <last_update_submitted_qc>January 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endocrine system</keyword>
  <keyword>neuroendocrine tumors</keyword>
  <keyword>neuroendocrine cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>neuroendocrine</keyword>
  <keyword>gastrointestinal (GI)</keyword>
  <keyword>high-dose octreotide</keyword>
  <keyword>flushing</keyword>
  <keyword>diarrhea</keyword>
  <keyword>quality of life in patients</keyword>
  <keyword>disease-related symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Serotonin Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was open to accrual at Moffitt Cancer Center 12/10/2013 through 10/10/2014.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Octreotide Long-acting Release (LAR)</title>
          <description>Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.
Octreotide LAR: Octreotide LAR as outlined in Treatment Arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Radiographic disease progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical progression due to disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants</population>
      <group_list>
        <group group_id="B1">
          <title>Octreotide Long-acting Release (LAR)</title>
          <description>Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.
Octreotide LAR: Octreotide LAR as outlined in Treatment Arm.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="53" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Improved Frequency of Diarrhea</title>
        <description>The frequencies of flushing, diarrhea, and carcinoid syndrome control rating (scale 1-5) will be measured and compared at week 0 and week 12 . These measurements will be compared using two-sided non-parametric paired Wilcoxon signed-rank.</description>
        <time_frame>At 12 weeks</time_frame>
        <population>Participants on study at 12 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Octreotide Long-acting Release (LAR)</title>
            <description>Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.
Octreotide LAR: Octreotide LAR as outlined in Treatment Arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improved Frequency of Diarrhea</title>
          <description>The frequencies of flushing, diarrhea, and carcinoid syndrome control rating (scale 1-5) will be measured and compared at week 0 and week 12 . These measurements will be compared using two-sided non-parametric paired Wilcoxon signed-rank.</description>
          <population>Participants on study at 12 weeks</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Progression Free Survival (PFS) at 6 Months</title>
        <description>Progression-free survival, defined as rate of patients alive and free of progression from the date of first study treatment to the end of trial at 6 months. Progressive disease (PD): at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>At 6 months</time_frame>
        <population>Evaluable participants on study at 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>Octreotide Long-acting Release (LAR)</title>
            <description>Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.
Octreotide LAR: Octreotide LAR as outlined in Treatment Arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Progression Free Survival (PFS) at 6 Months</title>
          <description>Progression-free survival, defined as rate of patients alive and free of progression from the date of first study treatment to the end of trial at 6 months. Progressive disease (PD): at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.</description>
          <population>Evaluable participants on study at 6 months</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Octreotide Long-acting Release (LAR)</title>
          <description>Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.
Octreotide LAR: Octreotide LAR as outlined in Treatment Arm.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Edema trunk</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was closed early due to slow accrual. There were no evaluable participants at 6 months for the planned Progression Free Survival measure.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jonathan Strosberg, M.D.</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-7257</phone>
      <email>jonathan.strosberg@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

